TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15507072
Drug: Diagnosis or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnosis or treatment for chronic pain
Study: 15507072
Drug: Differences in
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Differences in analgesic use across organizations
Study: 11411655
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (urethrocystoscopy)
Study: 18155445
Drug: Adjunctive lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive lamotrigine (LTG)
Study: 17063975
Drug: Dalteparin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (50 IU anti‐Xa/kg, single intravenous bolus)
Study: 11035679
Drug: 3.68 microm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.68 microm saline solution droplets inhaled for 30 s at 12 L/min
Study: 11035679
Drug: 3.68 microm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.68 microm saline solution droplets inhaled for 30 s at 31 L/min
Study: 11035679
Drug: 1.01 microm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.01 microm saline solution droplets inhaled for 30 s at 18 L/min
Study: 11035679
Drug: 1.01 microm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.01 microm saline solution droplets inhaled for 30 s at 38 L/min
Study: 1621545
Drug: Intracavernous E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracavernous E1 prostaglandin E1 (E1‐PG) injection
Study: 6326932
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiotherapy (40 Gy, one fraction a day over 20 days)
Study: 30560750
Drug: Multimodal analyses
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analyses with cognition plus any combination of one or more of the remaining three modalities
Study: 8834816
Drug: HSD-hCG vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSD-hCG vaccine
Study: 31644339
Drug: PO (unfed)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO (unfed) misoprostol (5 μg/kg)
Study: 31644339
Drug: PO (fed)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO (fed) misoprostol (5 μg/kg)
Study: 31644339
Drug: PR misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PR misoprostol (5 μg/kg)
Study: 23424263
Drug: Acupuncture in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture in combination with conventional therapy
Study: 17048209
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg/day (3 mg/m2 in children)
Study: 17048209
Drug: Irbesartan 300
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 300 mg/day (175 mg/m2 in children)
Study: 29102957
Drug: Stepwise dose
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepwise dose increase of febuxostat from 10 to 40 mg/day
Study: 29102957
Drug: Colchicine 0.5
Normalized name: colchicine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.5 mg/day plus fixed-dose febuxostat 40 mg/day
Study: 29102957
Drug: Fixed-dose febuxostat
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed-dose febuxostat 40 mg/day
Study: 27824913
Drug: Delays in
Normalized name: Delayed Release Oral Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delays in AED administration from seizure onset
Study: 25458644
Drug: Pioglitazone (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (titrated from 15 to 45 mg/d)
Study: 18833867
Drug: Nesiritide (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nesiritide (0.01 mcg/kg/min) in addition to maximal standard therapy
Study: 18833867
Drug: Maximal standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal standard therapy
Study: 12185153
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with lofepramine 70 mg and L-phenylalanine 500 mg twice daily, plus vitamin B-12 1 mg intramuscularly weekly.
Study: 12185153
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo tablets) plus vitamin B-12 1 mg intramuscularly weekly.
Study: 8908233
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ketorolac IV before surgery
Study: 6851412
Drug: Pentobarbital (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital (200 to 900 mg)
Study: 26537365
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose beetroot juice (H-BT; 250 ml)
Study: 26537365
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose beetroot juice (L-BT; 125 ml)
Study: 26537365
Drug: Isocaloric placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric placebo (PLA; 250 ml)
Study: 24898304
Drug: Albiglutide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide (30 mg, titrated to 50 mg)
Study: 24898304
Drug: Glimepiride (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (2 mg, titrated to 4 mg)
Study: 19442968
Drug: Cyclic user
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic user group receiving low-dose, monophasic OC pills for 24 months
Study: 19442968
Drug: Continuous user
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous user group receiving low-dose, monophasic OC pills for 24 months
Study: 19442968
Drug: Nonuser group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonuser group receiving no therapy
Study: 15774699
Drug: Endotracheal 13C-labeled
Normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Endotracheal 13C-labeled dipalmitoyl phosphatidylcholine administration
Study: 15177063
Drug: Primidone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primidone (500 mg daily)
Study: 10457295
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (10 mg/kg/day once daily)
Study: 10457295
Drug: Cefixime (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (10 mg/kg/day divided twice daily)
Study: 10457295
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (azithromycin, cefixime, no antibiotics)
Study: 1763537
Drug: Felodipine 5-40
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5-40 mg/d
Study: 6762118
Drug: 8.33 g/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.33 g/h of glucose during 6 hours
Study: 6762118
Drug: 16.66 g/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16.66 g/h of glucose during 6 hours
Study: 6762118
Drug: 16.66 g/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16.66 g/h of glucose with 20 mu insulin
Study: 6762118
Drug: 16.66 g/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16.66 g/h of glucose with 40 mu insulin
Study: 28694687
Drug: VApal ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: VApal ophthalmic solution (500 IU/mL)
Study: 25750345
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg ibandronate i.v.
Study: 25750345
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg zoledronic acid i.v.
Study: 19346816
Drug: Randomized phase
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized phase II trial and randomized discontinuation trial
Study: 17326546
Drug: 8 CBT
Normalized name: Octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8 CBT sessions (weekly)
Study: 17326546
Drug: No-treatment waiting
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment waiting period (WL)
Study: 15184276
Drug: Carvedilol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (50 mg/d) for 11 days
Study: 15184276
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate (190 mg/d) for 11 days
Study: 15184276
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate (190 mg/d)
Study: 12375800
Drug: Etoposide/cisplatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide/cisplatin therapy
Study: 7866846
Drug: 0.5 cc
Normalized name: SureComfort Pen 30g, 0.5 cc, 5/16 inches
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 cc of dye (Telebrix N, 30 g)
Study: 7866846
Drug: 1.0 cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 cc of dye (Telebrix N, 30 g)
Study: 7866846
Drug: 2.0 cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 cc of dye (Telebrix N, 30 g)
Study: 2503570
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of diflunisal given preoperatively
Study: 2503570
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of paracetamol (2 doses: preoperatively and 4 h postoperatively)
Study: 2503570
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (diflunisal and paracetamol)
Study: 346616
Drug: Halofenate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofenate treatment
Study: 30853151
Drug: IVIG plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG plus ciclosporin (5 mg/kg per day for 5 days)
Study: 30853151
Drug: IVIG (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (conventional treatment)
Study: 28025945
Drug: SpinalonTM (10-35
Approvals — FDA: no, EMA: no, PMDA: no
Description: SpinalonTM (10-35 mg buspirone/100-350 mg levodopa/25-85 mg carbidopa)
Study: 25845225
Drug: Flunarizine Hydrochloride
Normalized name: flunarizine hydrochloride
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine Hydrochloride Capsules (5 mg, twice daily for 5 days, then for two weeks in subsequent cycles)
Study: 25845225
Drug: Flunarizine Hydrochloride
Normalized name: flunarizine hydrochloride
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine Hydrochloride Capsules
Study: 23527716
Drug: Nebulised 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised 9 mg sodium hyaluronate plus saline solution
Study: 18462234
Drug: 4% icodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% icodextrin solution
Study: 17342946
Drug: Step down
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step down procedure for comparing several treatments
Study: 10193285
Drug: Dextromethorphan 27
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan 27 mg capsules, two doses before operation and three doses in the first 24 h after operation
Study: 10193285
Drug: Dextromethorphan 27
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan 27 mg capsules
Study: 3364636
Drug: nalbuphine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine 0.25 mg/kg
Study: 29449879
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Processing Therapy (CPT)
Study: 30137415
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment only
Study: 21484769
Drug: anti-tumor necrosis
Normalized name: G 1 (anti-tumor agent)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-tumor necrosis factor (anti-TNF) therapy
Study: 25748864
Drug: anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-TNF therapy
Study: 14528961
Drug: Single-channel maximum
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-channel maximum likelihood (ML) classifier (T2W)
Study: 11787477
Drug: β1-selective β-blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β1-selective β-blocker
Study: 30457900
Drug: Midazolam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (3 mg/kg)
Study: 30457900
Drug: Midazolam-butorphanol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam-butorphanol (3 mg/kg for each drug)
Study: 30457900
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline (0.9% NaCl) solution (control treatment)
Study: 24680549
Drug: Edoxaban 30mg
Normalized name: EDOXABAN 30MG TAB
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Edoxaban 30mg once daily
Study: 24680549
Drug: Enoxaparin 2000IU
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 2000IU twice daily
Study: 31351659
Drug: Cligosiban (400-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cligosiban (400-800 mg, taken 1 to 6 hours prior to sexual activity)
Study: 27502861
Drug: Bococizumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bococizumab (150 mg subcutaneously every 2 weeks)
Study: 25158896
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (40 mg methylprednisolone acetate mixed with 0.5 ml of 2% lidocaine) after 2 monthly saline placebo injections.
Study: 25158896
Drug: Dextrose injection
Normalized name: Dextrose Injection
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose injection (0.5 ml of 20% DX mixed with 0.5 ml of 2% lidocaine) repeated monthly for 3 months.
Study: 19347940
Drug: Combined low/high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined low/high power laser therapy
Study: 11440275
Drug: Plasma adrenomedullin
Normalized name: Adrenomedullin
DrugBank: Adrenomedullin (DB19102)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma adrenomedullin concentrations in patients with pheochromocytoma (37.9 +/- 6 pg/ml)
Study: 9763725
Drug: Low-dose phenobarbital
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose phenobarbital given daily for 3-7 days in conjunction with malaria therapy (artesunate or quinine + tetracycline)
Study: 9763725
Drug: Low-dose phenobarbital
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose phenobarbital with 5-day artesunate regimen
Study: 9763725
Drug: Low-dose phenobarbital
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose phenobarbital with quinine-tetracycline regimen
Study: 9763725
Drug: Low-dose phenobarbital
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose phenobarbital with dosing every 24 hours (artesunate)
Study: 8311270
Drug: 70 mL
Normalized name: ALCOHOL 70 mL TOPICAL SWAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mL of 0.25% ropivacaine
Study: 8311270
Drug: 70 mL
Normalized name: ALCOHOL 70 mL TOPICAL SWAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mL of 0.125% ropivacaine
Study: 29592840
Drug: Doravirine 100
Normalized name: doravirine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine 100 mg once daily plus two NRTIs (tenofovir and emtricitabine or abacavir and lamivudine)
Study: 29592840
Drug: Ritonavir-boosted darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted darunavir 800 mg plus two NRTIs (tenofovir and emtricitabine or abacavir and lamivudine)
Study: 27988146
Drug: Procaine benzylpenicillin
Normalized name: Procaine benzylpenicillin
DrugBank: Procaine benzylpenicillin (DB09320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Procaine benzylpenicillin and gentamicin once a day for 7 days (reference treatment)
Study: 27988146
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin twice daily and intramuscular gentamicin once a day for 7 days
Study: 27988146
Drug: Procaine benzylpenicillin
Normalized name: Procaine benzylpenicillin
DrugBank: Procaine benzylpenicillin (DB09320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Procaine benzylpenicillin and gentamicin once a day for 2 days followed by oral amoxicillin twice daily for 5 days
Study: 11297610
Drug: 22-kDa recombinant
Normalized name: Antihemophilic factor (recombinant), pegylated (20 kda)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22-kDa recombinant human GH (rhGH) at a dosage of 0.15 IU/kg/day for 1 week
Study: 8311540
Drug: Diclofenac/misoprostol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac/misoprostol (50 mg/200 micrograms twice daily)
Study: 8311540
Drug: Piroxicam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (10 mg twice daily)
Study: 8311540
Drug: Naproxen (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (375 mg twice daily)
Study: 30245114
Drug: Predictive scores
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive scores for NOMI based on risk factors identified (renal insufficiency, use of cardiopulmonary bypass, intra-aortic balloon pump support, reexploration for bleeding, renal replacement therapy, packed red blood cells ≥ 4 units)
Study: 22555773
Drug: 1.4 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 mg/m2 eribulin mesylate alone
Study: 22555773
Drug: 0.7 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 mg/m2 eribulin mesylate plus 200 mg ketoconazole
Study: 16150858
Drug: Exisulind 400
Normalized name: Exisulind
DrugBank: Exisulind (DB06246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exisulind 400 mg
Study: 16150858
Drug: Exisulind 200
Normalized name: Exisulind
DrugBank: Exisulind (DB06246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exisulind 200 mg
Study: 10898676
Drug: Abacavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir monotherapy (200, 400, or 600 mg every 8 hours [TID] and 300 mg every 12 h [BID]) for 4 weeks
Study: 10898676
Drug: Abacavir with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir with zidovudine (200 mg TID or 300 mg BID) for 8 weeks
Study: 10898676
Drug: Abacavir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir (300 mg BID) with zidovudine
Study: 1356527
Drug: Gonadotrophin releasing
Normalized name: Gonadotrophin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin releasing hormone (intranasally)
Study: 23009186
Drug: Ketamine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine with adjunctive atropine
Study: 23009186
Drug: Ketamine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine with adjunctive metoclopramide
Study: 12132062
Drug: IV nefopam
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV nefopam 0.15 mg/kg in 10 mL saline
Study: 12132062
Drug: IV tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tramadol 0.5 mg/kg in 10 mL saline
Study: 11136320
Drug: Curative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curative treatment for recurrence
Study: 3277562
Drug: Cefuroxime axetil,
Normalized name: Cefuroxime Axetil, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime axetil, 250 mg orally every 12 hours
Study: 3277562
Drug: Cefuroxime axetil,
Normalized name: Cefuroxime Axetil, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime axetil, 500 mg orally every 12 hours
Study: 3277562
Drug: Cefaclor, 500
Normalized name: Cefaclor, 500 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor, 500 mg orally every eight hours
Study: 21572151
Drug: ETN 25
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN 25 mg twice a week with 6‐8 mg/week MTX (E+M group)
Study: 18288617
Drug: Rebamipide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide (100 mg t.i.d)
Study: 8628335
Drug: Fish-oil preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil preparation (2.7 g of n-3 fatty acids daily)
Study: 8628335
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (daily)
Study: 8628335
Drug: Fish-oil preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil preparation
Study: 29489721
Drug: 1.2 g·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g·kg‐1 LMW (maltodextrin/dextrose/fructose)
Study: 29489721
Drug: 1.2 g·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g·kg‐1 HMW (Vitargo)
Study: 29489721
Drug: 0.066 g·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.066 g·kg‐1 PLA (noncaloric flavoring)
Study: 22393898
Drug: Bilastine 20
Normalized name: Bilastine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilastine 20 mg co-administered with ketoconazole 400 mg
Study: 16670121
Drug: Pediacel vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediacel vaccine
Study: 16670121
Drug: Diphtheria-tetanus-whole-cell pertussis-Haemophilus
Normalized name: DIPHTHERIA/HAEMOPHILUS/PERTUSSIS/POLIO/TETANUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria-tetanus-whole-cell pertussis-Haemophilus influenzae type b (DTwP-Hib) vaccine
Study: 16670121
Drug: DTwP-Hib vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTwP-Hib vaccine
Study: 15640461
Drug: Defatted rice
Normalized name: rice bran, defatted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defatted rice bran diet (13-22 g dietary fiber/d)
Study: 12198012
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation of 80 mg Cu (as copper sulfate). kg body wt(‐1). d(‐1) for 15 d
Study: 10192200
Drug: Interferon-alpha2a alone
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha2a alone (4.5 MIU thrice weekly for 6 months)